{"id":"pip-taz-fdc","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"1-5","effect":"Vomiting"},{"rate":"2-8","effect":"Rash"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Clostridium difficile-associated diarrhea"},{"rate":"1-2","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL302400","moleculeType":"Small molecule","molecularWeight":"861.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates many beta-lactamases, preventing bacterial resistance mechanisms that would otherwise destroy piperacillin. Together, they provide enhanced coverage against beta-lactamase-producing gram-positive and gram-negative bacteria, as well as anaerobes.","oneSentence":"PIP/TAZ is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) that works together to kill bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:14.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections)"}]},"trialDetails":[{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia","enrollment":274},{"nctId":"NCT02493764","phase":"PHASE3","title":"Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-24","conditions":"Bacterial Pneumonia","enrollment":537}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PIP/TAZ FDC","genericName":"PIP/TAZ FDC","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PIP/TAZ is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) that works together to kill bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}